Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALKSNASDAQ:INCYNASDAQ:NBIXNASDAQ:UTHR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$31.40-1.2%$31.26$22.90▼$36.45$5.24B0.511.76 million shs1.49 million shsINCYIncyte$62.11-0.7%$62.29$52.81▼$83.95$12.02B0.682.35 million shs1.82 million shsNBIXNeurocrine Biosciences$109.75+0.1%$106.03$84.23▼$157.98$10.85B0.261.07 million shs1.82 million shsUTHRUnited Therapeutics$298.70+1.4%$301.56$256.08▼$417.82$13.47B0.58440,706 shs295,744 shs10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes-1.20%+12.50%+4.46%+0.32%+30.56%INCYIncyte-0.67%+4.35%+2.53%-16.20%+15.53%NBIXNeurocrine Biosciences+0.06%+3.09%+14.74%-28.00%-22.00%UTHRUnited Therapeutics+1.39%+0.56%+2.13%-15.49%+13.83%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALKSAlkermes4.1382 of 5 stars3.31.00.04.22.02.51.9INCYIncyte4.7762 of 5 stars3.13.00.03.14.03.33.1NBIXNeurocrine Biosciences4.8801 of 5 stars4.43.00.02.92.72.53.1UTHRUnited Therapeutics4.985 of 5 stars4.34.00.04.63.43.33.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALKSAlkermes 2.67Moderate Buy$38.3322.08% UpsideINCYIncyte 2.17Hold$73.5318.39% UpsideNBIXNeurocrine Biosciences 2.86Moderate Buy$161.0546.74% UpsideUTHRUnited Therapeutics 2.67Moderate Buy$392.0031.24% UpsideCurrent Analyst Ratings BreakdownLatest ALKS, UTHR, INCY, and NBIX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2025NBIXNeurocrine BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$138.00 ➝ $139.005/6/2025NBIXNeurocrine BiosciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$158.00 ➝ $160.005/5/2025UTHRUnited TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$425.00 ➝ $425.005/2/2025ALKSAlkermesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$39.00 ➝ $40.005/2/2025ALKSAlkermesRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$38.00 ➝ $41.005/1/2025UTHRUnited TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$346.00 ➝ $348.005/1/2025UTHRUnited TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$355.00 ➝ $350.004/30/2025INCYIncyteWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$58.00 ➝ $59.004/30/2025INCYIncyteRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$64.00 ➝ $67.004/28/2025ALKSAlkermesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingUnderperform ➝ Underperform4/28/2025ALKSAlkermesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Perform ➝ Sector Perform(Data available from 5/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALKSAlkermes$1.51B3.42$2.36 per share13.32$9.05 per share3.47INCYIncyte$4.41B2.72$0.48 per share128.94$17.82 per share3.49NBIXNeurocrine Biosciences$2.36B4.61$3.20 per share34.35$25.97 per share4.23UTHRUnited Therapeutics$2.99B4.50$17.96 per share16.63$127.35 per share2.35Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALKSAlkermes$367.07M$2.0914.4722.922.2023.57%30.80%19.09%7/23/2025 (Estimated)INCYIncyte$32.62M$0.32230.059.500.410.77%0.05%0.04%N/ANBIXNeurocrine Biosciences$341.30M$3.2933.3616.960.7714.49%13.38%9.73%N/AUTHRUnited Therapeutics$984.80M$25.0613.1210.870.9740.31%19.22%16.15%N/ALatest ALKS, UTHR, INCY, and NBIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2025Q1 2025NBIXNeurocrine Biosciences$0.70$0.08-$0.62$0.08$587.06 million$572.60 million5/1/2025Q1 2025ALKSAlkermes$0.32$0.13-$0.19$0.13$307.53 million$306.51 million4/30/2025Q1 2025UTHRUnited Therapeutics$6.29$6.63+$0.34$6.63$726.82 million$794.40 million4/29/2025Q1 2025INCYIncyte$1.01$1.16+$0.15$0.80$996.17 million$1.05 billion2/26/2025Q4 2024UTHRUnited Therapeutics$6.10$6.19+$0.09$6.19$734.74 million$735.90 million2/12/2025Q4 2024ALKSAlkermes$0.81$0.92+$0.11$0.88$379.74 millionN/A2/10/2025Q4 2024INCYIncyte$1.57$1.09-$0.48$1.02$1.14 billionN/A2/6/2025Q4 2024NBIXNeurocrine Biosciences$1.62$1.00-$0.62$1.00$629.40 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALKSAlkermesN/AN/AN/AN/AN/AINCYIncyteN/AN/AN/AN/AN/ANBIXNeurocrine BiosciencesN/AN/AN/AN/AN/AUTHRUnited TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALKSAlkermesN/A3.042.65INCYIncyte0.011.971.94NBIXNeurocrine BiosciencesN/A3.403.28UTHRUnited TherapeuticsN/A4.584.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALKSAlkermes95.21%INCYIncyte96.97%NBIXNeurocrine Biosciences92.59%UTHRUnited Therapeutics94.08%Insider OwnershipCompanyInsider OwnershipALKSAlkermes4.40%INCYIncyte17.60%NBIXNeurocrine Biosciences4.30%UTHRUnited Therapeutics11.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALKSAlkermes2,280164.84 million154.66 millionOptionableINCYIncyte2,320193.57 million159.46 millionOptionableNBIXNeurocrine Biosciences1,20098.94 million95.42 millionOptionableUTHRUnited Therapeutics98045.09 million39.33 millionOptionableALKS, UTHR, INCY, and NBIX HeadlinesRecent News About These CompaniesFreestone Grove Partners LP Buys New Shares in United Therapeutics Co. (NASDAQ:UTHR)May 6 at 4:56 AM | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Given Average Rating of "Moderate Buy" by BrokeragesMay 6 at 2:27 AM | marketbeat.comUnited Therapeutics (UTHR) Receives Reiterated "Buy" Rating from HC Wainwright | UTHR ...May 5 at 8:08 AM | gurufocus.comUnited Therapeutics (NASDAQ:UTHR) Lowered to Buy Rating by StockNews.comMay 5 at 1:29 AM | americanbankingnews.comNorthern Trust Corp Grows Stake in United Therapeutics Co. (NASDAQ:UTHR)May 4 at 4:58 AM | marketbeat.comMorgan Stanley Issues Positive Forecast for United Therapeutics (NASDAQ:UTHR) Stock PriceMay 4 at 3:59 AM | americanbankingnews.comJPMorgan Chase & Co. Cuts United Therapeutics (NASDAQ:UTHR) Price Target to $350.00May 4 at 3:01 AM | americanbankingnews.comCaisse DE Depot ET Placement DU Quebec Has $137.64 Million Stock Position in United Therapeutics Co. (NASDAQ:UTHR)May 3 at 7:07 AM | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Holdings Raised by The Manufacturers Life Insurance CompanyMay 3 at 5:43 AM | marketbeat.comDistrict Court Dismisses Dispute Filed by United Therapeutics Against Liquidia | LQDA Stock NewsMay 2, 2025 | gurufocus.comLiquidia Technologies stock surges on legal winMay 2, 2025 | investing.comUnited Therapeutics (NASDAQ:UTHR) Shares Gap Up Following Strong EarningsMay 2, 2025 | marketbeat.comComerica Bank Increases Stock Position in United Therapeutics Co. (NASDAQ:UTHR)May 2, 2025 | marketbeat.comThe Top 3 Stock Picks at the World’s Greatest Hedge Fund (UTHR)May 2, 2025 | marketbeat.comEmerald Mutual Fund Advisers Trust Acquires 2,391 Shares of United Therapeutics Co. (NASDAQ:UTHR)May 2, 2025 | marketbeat.comTudor Investment Corp ET AL Increases Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)May 2, 2025 | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) Shares Gap Up After Better-Than-Expected EarningsMay 2, 2025 | americanbankingnews.comUnited Therapeutics (UTHR) Analyst Update: JP Morgan Maintains Rating | UTHR Stock NewsMay 1, 2025 | gurufocus.comUTHR Q1 Earnings & Revenues Beat Estimates on Higher Tyvaso SalesMay 1, 2025 | msn.comAQR Capital Management LLC Grows Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)May 1, 2025 | marketbeat.comUnited Therapeutics: Hold Rating Amid Strong Performance and Competitive ChallengesMay 1, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonBy The Associated Press | April 6, 2025View Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumUnited States Steel's Crash: An Unmissable Buying OpportunityBy Gabriel Osorio-Mazilli | April 11, 2025View United States Steel's Crash: An Unmissable Buying OpportunityALKS, UTHR, INCY, and NBIX Company DescriptionsAlkermes NASDAQ:ALKS$31.40 -0.38 (-1.20%) Closing price 05/5/2025 04:00 PM EasternExtended Trading$31.28 -0.11 (-0.37%) As of 08:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Incyte NASDAQ:INCY$62.11 -0.42 (-0.67%) Closing price 05/5/2025 04:00 PM EasternExtended Trading$61.86 -0.24 (-0.39%) As of 08:30 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.Neurocrine Biosciences NASDAQ:NBIX$109.75 +0.07 (+0.06%) Closing price 05/5/2025 04:00 PM EasternExtended Trading$123.66 +13.91 (+12.67%) As of 08:53 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.United Therapeutics NASDAQ:UTHR$298.70 +4.10 (+1.39%) Closing price 05/5/2025 04:00 PM EasternExtended Trading$298.41 -0.29 (-0.10%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Monster Beverage Stock: Short Report Risks vs Upside Potential Onsemi Stock Confirms Bottom, But What’s the Upside? 3 Reasons Tesla Should Be a $300 Stock by June Qualcomm: Analyst Opinions Split, But Upside Potential Remains Amazon: Why The Great Comeback Rally Could Be About to Begin Is Reddit Stock a Buy, Sell, or Hold After Earnings Release? MarketBeat Week in Review – 04/28 - 05/02 ExxonMobil: Production Offset Prices, Capital Return Safe in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
